In this episode of TechBio Talks, host Najat Khan, PhD, CEO and President of Recursion, talks to Dr. Morgan Cheatham, Partner and Head of Healthcare and Life Sciences at Breyer Capital, about how artificial intelligence and clinical data are converging to transform the measurement of human physiology and disease.

Morgan is a physician, medical geneticist, and investor who has spent nearly a decade backing category-defining companies spanning diagnostics, therapeutics, and care delivery.

They discuss how AI is reshaping the fundamentals of biotech value creation, the vital concept of ”modality market fit” for matching therapeutic architectures to patient tolerance, and why the ultimate moat in AI drug discovery is closing the loop between the wet lab, dry lab, and the clinic. Their conversation also covers how recasting medicine as an information science can collapse the barrier between scientific discovery and patient care delivery.

Chapters:

00:00 Introduction

00:57 The Role of Medical Geneticists in Healthcare

03:47 Investing: A Dual Perspective

04:46 Fundamentals of Biotech Value Creation

08:43 Private vs. Public Markets & Discontinuous Tech

12:00 Building the Ultimate Data Moat

13:43 AI as Measurement Tool in Healthcare

18:10 Unlocking Clinical Biobanks

20:42 Precision Therapy & Early Patient Selection

23:48 Defining Modality Market Fit

26:45 Designing for the Patient Experience

29:35 Medicine as an Information Science

31:42 Root Cause Analysis in Medicine and Innovation

33:42 Closing